Another cancer drug by Janssen unlikely to be available in Germany
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
Tag: G-BA
Federal Cabinet has agreed new law to stabilise SHI finances
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
How to bring innovation into German routine clinical practice?
Hello! In this week’s post, I am describing the G-BA’s initiative to promote innovation in the German health care system and clinical
What’s important to know about real-world evidence data collection in Germany?
In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since